<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967522</url>
  </required_header>
  <id_info>
    <org_study_id>ET19-006 - CABRAMET</org_study_id>
    <nct_id>NCT03967522</nct_id>
  </id_info>
  <brief_title>Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases</brief_title>
  <acronym>CABRAMET</acronym>
  <official_title>CABRAMET: A Phase 2 Study of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, exploratory, single-arm, prospective phase II study to
      assess the efficacy and safety profile of cabozantinib in patients with brain metastases from
      metastatic renal cell carcinoma (mRCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cabozantinib is a small molecule inhibitor of tyrosine kinases which include MET (hepatocyte
      growth factor receptor protein), VEGFR (vascular endothelial growth factor receptors), AXL,
      RET (Rearranged during transfection), FLT3 (Fms-like tyrosine kinase-3), KIT (mast/stem cell
      factor receptor), ROS1, MER, TYRO3, TRKB (Tropomyosin receptor kinase B) and TIE-2
      (angiopoietins receptor). Similar to other TKIs, cabozantinib is a reversible,
      ATP-competitive inhibitor. Cabozantinib has thus demonstrated significant activity in
      metastatic clear cell renal cell carcinoma after failure of one or 2 tyrosine kinase
      inhibitors and is now approved in the second line setting in Europe. Some efficacy was also
      demonstrated in patients in first line treatment when compared to sunitinib.

      Brain metastasis in renal cancer are difficult to treat and cytotoxic systemic therapies are
      still not used, given by the more or less impermeable blood-brain barrier. The interest of
      cabozantinib in brain renal cell carcinoma metastases is encouraged by 3 recent cases reports
      of significant responses of brain metastases including a complete response of brain
      metastases in one case. Moreover MET receptor surexpression appear more frequent in brain
      metastases than in other renal cell carcinoma tumor sites. Cabozantinib as multitarget
      inhibitor including VEGF and MET receptors suggest that it could be a good option. Its
      efficacy in brain metastases from renal cell carcinoma requires further evaluation.

      On this basis, the investigators propose to conduct an open-label exploratory single arm,
      multicenter prospective phase II trial to assess the efficacy of cabozantinib on brain
      metastases in metastatic renal cell carcinoma patients.

      Ancillary studies:

      The relationship between serum markers and efficacy data will be investigated. Serum and
      plasma sample will be collected at Baseline. MET expression and MET sequencing will be also
      performed on available tumor tissues.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2019</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The non progression rate in brain metastases at 3 months</measure>
    <time_frame>At 3 months for each patient</time_frame>
    <description>Tumor assessment in brain will be performed by cerebral MRI at baseline, 1.5 months and 3 months. These cerebral MRI will be reviewed by central review according to the RANO-BM criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 54 months</time_frame>
    <description>Assessed using the National Cancer Institute - Common Terminology Criteria for Adverse Event (NCI-CTCAE) v5 grading scale, specific registration of neurological event during study duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response in brain metastases</measure>
    <time_frame>Up to follow-up visit month 18 for each patient</time_frame>
    <description>Evaluated according to RANDO-BM criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in brain</measure>
    <time_frame>Up to 18 months for each patient</time_frame>
    <description>From the date of inclusion to the date of first documented disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 18 months for each patient</time_frame>
    <description>Measured from the date of inclusion to the date of first documented disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 54 months</time_frame>
    <description>Measured from the date of inclusion to the date of death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cabozantinib treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will be treated by 60 mg of cabozantinib once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>All participants will be treated by 60 mg of cabozantinib once daily. Temporary or permanent discontinuation and/or dose reduction of cabozantinib therapy may be required for the management of some adverse reactions. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.</description>
    <arm_group_label>Cabozantinib treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        I1. Age ≥ 18 years. I2. Histologically proven metastatic Renal Cell Carcinoma. I3. Brain
        metastases not requiring corticosteroids at dose &gt; 40 mg/day. I4.At least 1 brain lesion
        ≥8mm in longest diameter or &gt;5mm if &gt; 1 lesion. I5.Not previously treated by cabozantinib.
        I6.Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1. I7.Life
        expectancy ≥ 3 months

        I8.Adequate organ function as defined by the following criteria:

          -  Total serum bilirubin ≤ 2 x ULN (Gilbert's disease exempted)

          -  Serum transaminases and alkaline phosphatases ≤ 2.5 x ULN, or in case of liver or bone
             metastasis ≤ 5.0 x ULN

          -  Serum creatinine ≤ 2 x ULN, creatinine clearance ≥ 50 ml/min

          -  Absolute neutrophil count (ANC) ≥ 1 500/mm3

          -  Platelets ≥ 100 000/mm3 (100 G/l)

          -  Hemoglobin ≥ 9.0 g/dl. I9. Covered by a medical/health insurance. I10. Willingness and
             ability to comply with scheduled visits, treatment plans, laboratory tests, and other
             study procedures.

        I11. Signed and dated IRB/ICE approved informed consent form. I12. Accepting to use
        effective contraception (barrier contraceptives) during study treatment and within at least
        4 months after final dose of study therapy. Oral contraceptives are not acceptable.

        Exclusion Criteria:

        E1. Any local previous treatment of current brain metastases. E2. Any anti-coagulation
        therapy (except preventive treatment at low dose). E3. Contra-indication of Magnetic
        Resonance Imaging (MRI) (i.e. : pace-maker). E4. Uncontrolled seizures. E5. Any symptoms of
        intracranial hypertension. E6. Any of the following within 12 months prior to treatment
        initiation: severe/unstable angina, myocardial infarction, coronary artery bypass graft,
        symptomatic congestive heart failure, ischemic or hemorrhagic stroke including transient
        ischemic attack.

        E7. Uncontrolled hypertension defined as systolic blood pressure &gt;150 mmHg or diastolic
        pressure &gt;90 mmHg, despite optimal medical treatment.

        E8. Ongoing cardiac dysrhythmia of grade ≥ 2, atrial fibrillation of any grade, QTc
        interval &gt; 0.43.

        E9. Pregnant or breast feeding woman (mandatory negative serum or urinary pregnancy test at
        study entry for all women of childbearing potential).

        E10. Any acute or chronic medical or psychiatric condition or laboratory abnormality that
        would make the patient unsuited to study participation.

        E11. Any second malignancy within the last 3 years with the exception of basal cell
        carcinoma, in situ cervical cancer and pT1/a bladder cancer with no evidence of recurrent
        disease for 12 months.

        E12. Patients receiving strong inhibitor or inducer of CYP3A4 especially some
        anti-epileptic drugs.

        E13. Psychological, familial, sociological, geographical conditions that would limit
        compliance with study protocol requirements.

        E14. Participation to another clinical trial that might interfere with the evaluation of
        the main criterion.

        E15. Known hypersensitivity to the active substance or to any of the excipients of
        cabozantinib.

        E16. Patient requiring tutorship or curatorship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie NEGRIER, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvie NEGRIER, MD, PhD</last_name>
    <phone>0478782751</phone>
    <phone_ext>+33</phone_ext>
    <email>sylvie.negrier@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest-Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Remy DELVA, MD</last_name>
      <phone>+332.41.35.27.00</phone>
      <email>remy.delva@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Besancon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien CALCAGNO, MD</last_name>
      <phone>+33381668705</phone>
      <email>f.calcagno@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain LADOIRE, MD</last_name>
      <phone>+333 80 73 75 28</phone>
      <email>sladoire@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie NEGRIER, MD, PhD</last_name>
      <phone>+334 78 78 27 51</phone>
      <email>sylvie.negrier@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34928</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diego TOSI, MD</last_name>
      <phone>+334.67.61.23.04</phone>
      <email>diego.tosi@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Lorraine</name>
      <address>
        <city>Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionnel GEOFFROIS, MD</last_name>
      <phone>+333 83 59 83 31</phone>
      <email>l.geoffrois@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest-site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric ROLLAND, MD</last_name>
      <phone>+332.40.67.99.76</phone>
      <email>frederic.rolland@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUCT-Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine CHEVREAU, MD</last_name>
      <phone>+335 31 15 51 51</phone>
      <email>chevreau.christine@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence ALBIGES, MD</last_name>
      <phone>+331 42 11 62 64</phone>
      <email>laurence.albiges@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mRCC</keyword>
  <keyword>cabozantinib</keyword>
  <keyword>brain metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

